Liver Cancer Clinical Trials
Clinical trials are studies conducted on volunteers using investigational treatments or methods. The decision to enroll in a trial should be based on concrete information and eligibility depends on many factors.
For more information about HCC clinical trials in your area, visit www.clinicaltrials.gov.
Discuss the advantages, disadvantages, and side effects of treatment options with your doctor.
Ask your doctor about the possibility of using experimental therapies and eligibility to participate in clinical trials. If you want to participate in a clinical trial, ask what is the phase of the trial.
Consider seeking a second opinion if your health insurance allows you the option to do so.
LIVER CANCER CLINICAL TRIALS (featured listings)
Blue Faery does not endorse, sponsor or recommend any specific clinical trial. An asterisk indicates a paid listing.
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
Official Title: An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)
Condition: Hepatocellular Carcinoma
Intervention/Treatment: TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab (Imjudo) immunotherapy
Phase: Phase 2
Study Type: Interventional (Clinical Trial)
Study Design: 100 patients, Global, Open-label, Single arm
Primary Purpose: Treatment
For more information, contact Patrice Feaster, Clinical Trial Manager
Email: Patrice.feaster@bsci.com
Website: https://www.bostonscientific.com/en-US/medical-specialties/interventional-radiology/interventional-oncology/therasphere/clinical-data/rowan-study.html
Business Phone: (240) 204-1317
Boston Scientific
1 SciMed Place, Maple Grove,
MN 55331,
United States
Listed on 4/5/2024
The purpose of this study is to characterize the safety and efficacy of atezolizumab plus bevacizumab or atezolizumab alone (in patients who are ineligible for bevacizumab) in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh B7 or B8 liver cirrhosis.
Official Title: A Phase II, Open-Label, Multi-Cohort, Multicenter Study In Patients With Unresectable Hepatocellular Carcinoma And Child-Pugh B7 And B8 Cirrhosis
Condition: Hepatocellular Carcinoma
Intervention/Treatment: Atezolizumab, Bevacizumab
Phase: Phase 2
Study Type: Interventional (Clinical Trial)
Study Design: 120 patients total; Cohort A: atezolizumab + bevacizumab Cohort B: atezolizumab (for patients ineligible to Cohort A) The study is designed to non-comparatively evaluate the safety and efficacy of atezolizumab plus bevacizumab or atezolizumab monotherapy in this population.
Primary Purpose: Treatment
For more information, contact Olivia Oliveros-Cuenos, Senior Clinical Trial Leader
Email: oliveroo@gene.com
Business Phone: (650) 438-6991
Genentech
1 DNA Way South,
San Francisco, CA 94080
United States
Listed on 2/15/24
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib and lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with cabozantinib or lenvatinib may kill more tumor cells in patients with liver cancer.
Official Title: A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects With Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab
Condition: Hepatocellular Carcinoma
Intervention/Treatment: Atezolizumab, Cabozantinib or Lenvatinib
Phase: Phase 2
Study Type: Interventional (Clinical Trial)
Study Design: 122 participants are randomized to 1 of 2 arms. ARM A: Patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1 and cabozantinib orally (PO) once daily (QD) or lenvatinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive cabozantinib PO QD or lenvatinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Primary Purpose: Treatment
For more information, contact Madi Arshad, Research Protocol Specialist
Email: ACCRU@mayo.edu
Website: hhttp://accrunetwork.org/
Business Phone: (507) 266-1090
Mayo Clinic
200 First Street SW,
Rochester, MN 55905
United States
Listed on 2/14/24
This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population.
Official Title: A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC)
Condition: Resectable Hepatocellular Carcinoma
Intervention/Treatment: Atezolizumab, Tiragolumab, Bevacizumab, Tobemstomig
Phase: Phase 1b/2
Study Type: Interventional (Clinical Trial)
Study Design: 150 pt study total; 50 pts/arm across 3 arms (30 preliminary + 20 expansion) with optional adjuvant Atezo+Bev. Preliminary phase will include 10 pt safety evaluation phase. Neoadj arms: Atezo+Bev; Atezo+Bev+Tira; Tobe+Bev (3 cycles prior to surgery)
Primary Purpose: Treatment
For more information, contact Janet Lau, Clinical Scientist
Email: lau.janet@gene.com
Website: https://www.gene.com
Business Phone: (650) 255-3760
Genentech
1 DNA Way, 40-5A South,
San Francisco CA 94080
United States
Listed on 10/20/23
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.
Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
Official Title: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Condition: Hepatocellular Carcinoma
Intervention/Treatment: Atezolizumab, tiragolumab, bevacizumab, tobemstomig, tocilizumab, TPST-1120, ADG126
Phase: Phase 1b/2
Study Type: Interventional (Clinical Trial)
Study Design: 220-400 patients enrolling into a 1L HCC Cohort; 20-60 patients/arm; 8 arms (7 experimental and 1 control [Atezo+Bev])
Primary Purpose: Treatment
For more information, contact Ritu Malhotra, Senior Clinical Scientist
Email: malhotr2@gene.com
Website: https://www.gene.com
Business Phone: (650) 863-6177
Genentech
1 DNA Way, 40-5A South,
San Francisco CA 94080
United States
Listed on 10/20/23
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).
Official Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention/Treatment: Atezolizumab, tiragolumab, bevacizumab, placebo
Phase: Phase 3
Study Type: Interventional (Clinical Trial)
Study Design: 650 patients randomized in a 1:1 fashion into two arms: Arm A: tiragolumab + atezolizumab+ bevacizuamb Arm B: placebo + atezoizumab + bevacizumab
Primary Purpose: Treatment
For more information, contact Chris Cotter, Senior Clinical Scientist
Email: cotterc1@gene.com
Website: https://www.gene.com
Business Phone: (631) 383-1379
Genentech
1 DNA Way, 40-5A South,
San Francisco CA 94080
United States
Listed on 10/20/23
The objective of this pivotal study is to evaluate the safety and effectiveness of SIRT using SIR-Spheres Y-90 resin microspheres as first-line treatment for local control of HCC in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2, and C.
Official Title: A Prospective, Multicenter, Open-label Single Arm Study Evaluating the Safety & Efficacy of Selective Internal Radiation Therapy Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
Intervention/Treatment: SIR-Spheres Y-90 resin microspheres
Phase: Not Applicable
Study Type: Interventional (Clinical Trial)
Study Design: Open-label, Single arm
Primary Purpose: Treatment
For more information, contact David Jackson MD
Email: david.jackson@sirtex.com
Business Phone: (888) 474-7839
Sirtex Medical Inc.
300 Unicorn Park Drive, 2nd Floor,
Woburn, MA 01801
United States
Listed on 9/18/23
This is a Phase III, parallel, randomized, open-label, sponsor-blinded, 3-arm, multicenter, international study assessing the efficacy and safety of durvalumab + tremelimumab + TACE with or without lenvatinib compared with TACE alone in participants with locoregional HCC not amenable to curative therapy (eg, surgical resection, transplantation, or ablation).
Official Title: A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-3)
Intervention/Treatment: Durvalumab / Tremelimumab / Lenvatinib / TACE
Phase: Phase III
Study Type: Interventional (Clinical Trial)
Study Design: Parallel assignment
Primary Purpose: Treatment
For more information, contact James Osborne, Global Clinical Operations Program Director
Email: emerald3@astrazeneca.com
Website: https://astrazenecagrouptrials.pharmacm.com/
Business Phone: (877) 240-9479
AstraZeneca
200 Orchard Ridge Drive
Gaithersburg, MD 20878
United States
Map It
Relisted on 8/8/23
The purpose of this study is to assess the safety and tolerability of ET140203 T cells in pediatric patients with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Malignant Neoplasm, Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC) and to determine the recommended Phase 2 dose (RP2D). ET140203 T cells are autologous T cells engineered to specifically recognize and kill AFP/HLA-A2 positive liver cancer cells.
Official Title: An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)
Condition: Hepatoblastoma (HB), Hepatocellular Malignant Neoplasm, Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)
Intervention/Treatment: ET140203 autologous T cells
Phase: Phase I/II
Study Type: Interventional (Clinical Trial)
Study Design: Sequential Assignment, Open Label
Primary Purpose: Treatment
For more information, please reach out:
Email: eurekaconnectme@eurekainc.com
Website: https://www.eurekaconnectme.com
Phone (510) 722-8719
Business Phone: (510) 654-7045
Eureka Therapeutics, Inc.
5858 Horton Street, Suite 170
Emeryville, CA 94608
United States
Map It
Listed on 11/8/21
The purpose of this study is to assess the safety and tolerability of ECT204 T cells in adult patients with glypican-3 (GPC3) positive hepatocellular carcinoma (HCC) and to determine the recommended Phase 2 dose (RP2D). ECT204 T cells are autologous T cells engineered to specifically recognize and kill GPC3 positive liver cancer cells.
Official Title: An Open-Label, Dose-Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3)
Condition: Advanced hepatocellular carcinoma
Intervention/Treatment: ECT204 T cells
Phase: Phase I/II
Study Type: Interventional (Clinical Trial)
Study Design: Sequential Assignment, Open Label
Primary Purpose: Treatment
For more information, reach out
Email: eurekaconnectme@eurekainc.com
Website: https://www.eurekaconnectme.com
Phone (510) 722-8719
Business Phone: (510) 654-7045
Eureka Therapeutics, Inc.
5858 Horton Street, Suite 170
Emeryville, CA 94608
United States
Map It
Listed on 7/22/21
The purpose of this study is to assess the safety and tolerability of ET140203 T cells in adult patients with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC) and to determine the recommended Phase 2 dose (RP2D). ET140203 T cells are autologous T cells engineered to specifically recognize and kill AFP/HLA-A2 positive liver cancer cells.
Condition: Advanced Hepatocellular Carcinoma
Intervention: ET140203 T cells
Phase: Phase I/II
Study Type: Interventional (Clinical Trial)
Study Design: Sequential Assignment, Open Label
Primary Purpose: Treatment
For more information, reach out
Email: eurekaconnectme@eurekainc.com
Website: https://www.eurekaconnectme.com
Phone (510) 722-8719
Business Phone: (510) 654-7045
Eureka Therapeutics, Inc.
5858 Horton Street, Suite 170
Emeryville, CA 94608
United States
Map It
Listed on 6/12/21
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar)
This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in treating patients with liver cancer that cannot be removed by surgery after undergoing standard high-dose external beam radiotherapy. Autologous dendritic cells are immune cells generated from patients' own white blood cells that are grown in a special lab and trained to stimulate the immune system to destroy tumor cells. A pneumonia vaccine called Prevnar may also help stimulate the immune system. Giving autologous dendritic cells and Prevnar to patients with live cancer after radiotherapy may help doctors determine if it is possible to stimulate the body's own immune system to fight against the tumor, and to see if this immune stimulation can be done safely.
Condition: Hepatocellular carcinoma
Intervention: Combination of external beam radiation therapy, pneumonia (Prevnar) vaccine and autologous dendritic cells
Phase: Phase 1
Study Type: Interventional (Clinical Trial)
Study Design: Single arm, open label
Primary Purpose: Treatment
For more information, contact Dr. Lewis Roberts, Director, Hepatobiliary Neoplasia Clinic
Email: Roberts.Lewis@mayo.edu
Website: https://www.mayo.edu/research/faculty/roberts-lewis-r-m-b-ch-b-ph-d/bio-00084430
Phone (507) 266-3239
Mayo Clinic
200 First Street SW
Rochester, MN 55905
United States
Map It
Listed on 9/22/20